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(57) ABSTRACT 
Disclosed herein are methods and compositions of treating a 
subject suffering from a wound. In exemplary examples, the 
method involves elevating MCPIP levels in a subject in need. 
Elevating MCPIP levels may involve direct administration 
(e.g. delivery of protein) or indirect administration (e.g. deliv-
ery vehicle capable of increasing expression of MCPIP). 
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1 
MCPIP AS WOUND THERAPY 
RELATED APPLICATIONS 
2 
infection starts, the infection may be very difficult to reverse, 
and amputation of the affected limb is common. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1. Expression of MCPIP on scratch-induced wound 
healing in HaCaT cells. (A) Cells were cultured to confluence 
and transfected with GFP or MCPIP vectors for 48 hrs and 
This application is a continuation of U.S. Ser. No. 13/804, 5 
275 filed Mar. 14, 2013, now issued as U.S. Pat. No. 8,703, 
703, which is a continuation-in-part of U.S. Ser. No. 12/539, 
907 filed Aug. 12, 2009, now abandoned, which is a 
continuation of U.S. Ser. No. 11/643,057 filed Dec. 20, 2006, wounded by scratching. Cells were then incubated for the 
now abandoned, which are incorporated herein in their 10 indicated hours and photographed. (B) Quantification of 
entirety by reference. scratch-induced wound healing during 24 hrs after scratch-
BACKGROUND 
Generally, when the skin of an individual is torn, cut or 
punctured (wounded), the body naturally reacts to regenerate 
dermal and epidermal tissue to close the wound. The wound 
regeneration process typically includes a set of complex bio-
chemical events that take place in a closely orchestrated cas-
cade to repair the damage. These events overlap in time, but 
may be categorized into different phases, namely the inflam-
matory, proliferative, and remodeling phases. 
ing. 
FIG. 2. Knockdown of MCPIP inhibited migration of 
HaCaT cells. (A) HaCaT cells were cultured and transfected 
15 with MCPIP siRNA or non-targeted siRNA for 48 hrs, RT-
PCR was performed to confirm that siRNA efficiently knock-
down of MCPIP mRNA levels. (B) Cells were cultures to 
confluence and wounded by scratching. Cells were then incu-
bated for the indicated hours and photographed. (C) Quanti-
20 fication of cell migration during 24 h after scratching. 
FIG. 3. Lack ofMCPIP impaired wound healing in MCPIP 
KO mice. (A) Wound sites were photographed at the indi-
cated time. (B) Changes in percentage of wound area at each 
time point compared with the original wound area. 
FIG. 4. Expression ofMCPIP enhanced wound healing in 
diabetic mice. (A) Induction of MCPIP was found in the 
wound skin but not in the healed skin. (B) Wound sites were 
photographed at the indicated time. Day 0 pictures were taken 
immediately after the wound. (C) Changes in percentage of 
In the inflammatory phase, bacteria and debris are phago-
cytized and removed, and factors are released that cause the 25 
migration and division of cells involved in the proliferative 
phase. In the proliferative phase, the principal steps include 
angiogenesis, fibroplasias, granulation tissue formation, epi-
thelialization, and wound contraction. Angiogeneis involves 
the development of new capillary blood vessels for the wound 
area to provide oxygen and nutrients to the healing tissue. In 
fibroplasia and granulation tissue formation, fibroblasts grow 
and form a new, provisional extracellular matrix (ECM) by 
excreting collagen and fibronectin. In epithelialization, epi-
thelial cells crawl across the wound bed to cover the bed. In 35 
30 wound area at each time point compared with the original 
wound area. (D) Expression of cytokines in wound skins at 
day 12 after wound. (F) Expression of PECAM and VEGF in 
wound skins at day 12 was examined by RT-PCR. 
DETAILED DESCRIPTION 
contraction, the wound is made smaller by the action of 
myofibroblasts, which establish a grip on the wound edges 
and contract themselves using a mechanism similar to that in 
smooth muscle cells. When the cells' roles are close to com-
plete, urmeeded cells undergo apoptosis. 
It is known that a number of disease states hinder the 
normal wound healing process. For example, individuals with 
diabetes often experience problems with what are termed 
"diabetic foot ulcers." Diabetic foot ulcers are sores or 
wounds, typically, on the feet that typically occur in individu-
als having diabetes. Oftentimes, these diabetic ulcers occur as 
a direct or indirect result of nerve damage in the feet of the 
individual as the prolonged high blood sugar levels associated 
with diabetes is linked with damage to the nerves in the feet. 
Such nerve damage in the feet, referred to as peripheral neu-
ropathy, can cause loss of sensation as well as cause defor-
mities of the feet. Due to the loss of sensation, individuals 
with peripheral neuropathy may hurt their feet by repetitive 
minor trauma (e.g., by prolonged walking) or a single major 
trauma (e.g., by scraping skin, stepping on objects, immers-
ing feet in hot water, cutting toenails inappropriately, or wear-
ing ill-fitting shoes), but nevertheless may not notice such 
injuries. A further complication of diabetes is a reduction in 
blood flow to the feet due to the arterial blockage or other 
causes, thereby severely inhibiting the body's ability to 
adequately provide complete the proliferative stage of wound 
regeneration/healing described above. As a result, once the 
skin of the foot is torn, cut, or punctured, the wound healing 
process (e.g., the proliferative phase) may be inordinately 
slow in repairing the wound. Further, once a serious wound 
develops, the risk ofinfection is high as the individual's body 
is simply unable to heal the wound. Even further, once an 
The inventors have previously identified the novel tran-
scription factor designated as MCPIP (MCP-1-induced pro-
tein). MCPIP was initially isolated from human monocytes 
40 after stimulation with MCP-1. The nucleotide (SEQ ID NO: 
1) and amino acid (SEQ ID NO: 2) sequences of isolated 
human MCPIP were deposited with GenBank under acces-
sion number AY920403 and the nucleotide (SEQ ID NO: 3) 
and amino acid (SEQ ID NO: 4) sequences of isolated mouse 
45 MCPIP were deposited with GenBank under accession num-
ber AY920404. The inventors have continued to study the 
biological relevance of these genes/proteins, and to develop 
new therapies based on this research. The invention is based 
on the inventors discovery that maintaining or elevating 
50 MCPIP levels can accelerate wound healing in a subject. 
According to one embodiment, the invention pertains to a 
method of treating wounds. MCPIP may be elevated by direct 
administration of a composition. The composition may com-
prise a therapeutically effective amount of the MCPIP pro-
55 tein. The MCPIP protein composition may comprise a phar-
maceutically acceptable excipient. Alternatively, MCPIP 
may be elevated by administering a composition comprising 
a delivery vehicle that results in the in vivo expression of 
MCPIP. In yet another embodiment, MCPIP is elevated by 
60 inducing expression of the endogenous gene. 
As used herein, the use of the word "a" or "an" when used 
in conjunction with the term "comprising" in the claims and/ 
or the specification may mean "one," but it is also consistent 
with the meaning of"one or more," "at least one," and "one or 
65 more than one." 
The term "wound" as used herein refers to any break in the 
epithelium resulting from a cut, abrasion, adhesion, surgical 
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3 
incision, thermal, chemical, or friction bum, ulcer, or the like, 
as a result of an accident, incident, surgical procedure, or the 
like. Wound can be further defined as acute and/or chronic. 
Compositions of the present invention have been found to be 
particularly useful in the treatment of diabetic ulcers, which 
are a type of wound as defined herein. 
The term "pharmaceutical composition" as used herein 
refers to a wound composition as described herein that this 
dispersed in a pharmaceutically acceptable carrier. 
The term "subject" as used herein refers to any human or 
nonhuman mammalian animal to which a wound composi-
tion is administered according to the methods described 
herein. In a specific embodiment, the compositions and meth-
ods of the present invention are employed to treat a human 
subject. 
The term "effective amount" or "therapeutically effective 
amount" as used herein refer to an amount effective, at dos-
ages and for periods of time necessary to achieve a desired 
result. The desired result may be an improvement in the 
wound healing process (e.g., by reducing a surface area of the 
wound), remediation of the symptoms of the wound (e.g., 
pain, infection, and the like), shortening of the duration of any 
stage in the wound healing process, stabilization of the state 
of wound (e.g., infection), prevention or slowing of the devel-
opment of wound progression, prevention of, delay or slow-
ing of wound progression, delay or slowing of wound onset, 
amelioration or palliation of the wound state, and remission 
(whether partial or total), whether detectable or undetectable. 
The term "topical administration" as used herein includes 
the contact of the wound compositions of the present inven-
tion with tissue on or about the wound area. 
The term "parenteral administration" as used herein 
includes any form of administration in which a composition is 
delivered or absorbed into the patient without involving 
absorption via the intestines. Exemplary parenteral adminis-
trations that are used in the present invention include, but are 
not limited to intradermal or subcutaneous administration. 
The term "treating" and "treatment" as used herein refers to 
an approach for obtaining beneficial or desired results, 
including clinical results. Beneficial or desired clinical results 
can include, but are not limited to, an improvement in the 
wound healing process (e.g., by reducing a surface area of the 
wound), remediation of the symptoms of the wound (e.g., 
pain, infection, and the like), shortening of the duration of any 
stage in the wound healing process or the overall wound 
healing process, stabilization of infection (if any), and remis-
sion (whether partial or total), whether detectable or unde-
tectable. 
Compounds and Compositions 
The compounds described herein may be provided in any 
suitable form for administration to a wound of a patient. In 
one embodiment, the compounds are provided as pharmaceu-
tical composition comprising a pharmaceutically acceptable 
carrier. In a typical embodiment, the compound is MCPIP or 
a variant or derivative thereof. 
In one aspect, the pharmaceutically acceptable carrier may 
comprise a substrate, such as a natural or synthetic non-
woven or woven material, having the Compounds disposed 
on and/or therein to define a dressing that can be applied to, 
about, or adjacent to a wound. The substrate defining the 
dressing may be selected from the group consisting of a 
transdermal patch, a pad, a powder, a bandage, a host matrix, 
4 
20120282320, the entirety of which is hereby incorporated by 
reference. The Compounds may be impregnated within, oth-
erwise dispersed within, and/or applied to a surface of the 
dressing using any suitable technique known in the art, such 
as by coating, spraying or dipping. It is appreciated that the 
dressing may include a polymeric coating or surface to be 
placed in contact with the wound, such as Teflon®, to avoid 
sticking of the dressing to the wound. 
In addition, the wound compositions of the present inven-
lO tion may be provided and/or manufactured as a pharmaceu-
tical composition for topical administration, parenteral 
administration, and/or any other suitable administration. It is 
understood that the active ingredient( s) and pharmaceutically 
15 
acceptable carrier may be provided individually (with or 
without instructions for future mixing) or together (mixed, 
non-mixed, or with instructions for future mixing) in the 
respective formulation. Further, the wound composition may 
be prepared by known methods for the preparation of phar-
20 maceutically acceptable compositions suitable for adminis-
tration to a patient, such that an effective quantity of the active 
ingredients is combined in a mixture with a pharmaceutically 
acceptable carrier. Suitable pharmaceutically acceptable car-
riers are described, for example, in Remington's Pharmaceu-
25 tical Sciences (Remington's Pharmaceutical Sciences, Mack 
Publishing Company, Easton, Pa., USA 1985). 
In one embodiment, the wound composition is provided in 
the form of a topical composition that can be applied to, over, 
or adjacent the wound area. Without limitation, the topical 
30 composition may be in the form of a solution, a suspension, a 
spray, a cream, a gel, a foam, an ointment, a lotion, or a 
powder. The wound composition may be formulated as a 
controlled release, delayed release, or a sustained release 
35 
formulation as is known in the art. 
When a wound composition of the present invention is 
provided in the form of a topical composition, the wound 
composition may further include other cosmetic ingredients 
and pharmaceutically acceptable topical carriers which have 
40 substantially non-irritating, skin compatible components. 
Such suitable cosmetic and pharmaceutical agents include, 
but are not limited to, moisturizers, stabilizers, preservatives, 
antiseptics, lubricants, humectants, gelling agents, chelating 
agents, skin penetration enhancers, emollients, colorants, sol-
45 vents, fatty bodies, thickening agents, emulsifiers, and/or any 
other excipient(s ), which do not alter the therapeutic effect of 
the active ingredient(s) therein, e.g., Compounds. 
In certain embodiments, the pharmaceutically acceptable 
carrier may include one or more of emulsifying agents, inert 
50 carriers including hydrocarbon bases, emulsifying bases, 
non-toxic solvents or water-soluble bases. Particularly suit-
able examples include pluronics, HPMC, CMC and other 
cellulose-based ingredients, lanolin, hard paraffin, liquid par-
affin, soft yellow paraffin or soft white paraffin, white bees-
55 wax, yellow beeswax, cetostearyl alcohol, cetyl alcohol, 
dimethicones, emulsifying waxes, isopropyl myristate, 
microcrystalline wax, oleyl alcohol and stearyl alcohol. 
Exemplary topical formulations to which the Nanopar-
ticles may be included are set forth in U.S. Published Patent 
60 Application No. 20120289579, the entirety of which is 
hereby incorporated herein. It is appreciated that the active 
ingredient(s) described herein, e.g., Compounds, could 
replace or augment the active ingredient(s) described in U.S. or any other suitable substrate configured to be applied to, 
over, and/or adjacent the wound. In certain embodiments, the 
dressing comprising the Compounds may be a hemostatic 65 
dressing as is known in the art. Exemplary hemostatic dress-
ings are described in US Published Patent Application No. 
Published Patent Application No. 20120289579. 
The concentration of active compound in the pharmaceu-
tical composition will depend on absorption, inactivation and 
excretion rates of the active compound, the physicochemical 
US 8,999,314 B2 
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characteristics of the compound, the dosage schedule, and 
amount administered as well as other factors known to those 
of skill in the art. 
Typically a therapeutically effective dosage should pro-
duce a serum concentration of active compound of from about 
0.1 ng/ml to about 50-100 µg/ml. The pharmaceutical com-
positions typically should provide a dosage of from about 
0.001 mg to about 2000 mg of compound per kilo-gram of 
body weight per day. Pharmaceutical dosage unit forms are 
prepared to provide from about 1 mg to about 1000 mg and 10 
preferably from about 10 to about 500 mg of the essential 
active ingredient or a combination of essential ingredients per 
dosage unit form. 
The active compound may be administered at once, or may 
be divided into a number of smaller doses to be administered 15 
at intervals of time. It is understood that the precise dosage 
and duration of treatment is a function of the disease being 
treated and may be determined empirically using known test-
ing protocols or by extrapolation from in vivo or in vitro test 
data. It is to be noted that concentrations and dosage values 20 
may also vary with the severity of the condition to be allevi-
ated. It is to be further understood that for any particular 
subject, specific dosage regimens should be adjusted over 
time according to the individual need and the professional 
judgment of the person administering or supervising the 25 
administration of the compositions, and that the concentra-
tion ranges set forth herein are exemplary only and are not 
intended to limit the scope or practice of the claimed compo-
sitions. 
6 
ciated with a particular disorder or condition, which renders 
the subject susceptible to, indirectly causes, or directly causes 
a non-healing wound. In certain embodiments, the subject is 
a diabetic, for example. 
Kits 
The compositions described herein may be provided in 
suitable packaging for maintaining the integrity of the article. 
In addition, the article may be provided as a kit along with 
suitable instructions that direct a user to use of a wound 
composition, e.g., pharmaceutical composition or dressing, 
comprising the Compounds in the treatment of a wound in a 
subject. The instructions may comprise user-readable and/or 
computer-readable information embodied on any suitable 
medium, such as a paper insert or a computer-readable disc. 
Alternatively, the instructions may direct the user to an exter-
nal source, such as to a website, where such instructions may 
be found. 
Dosing 
One skilled in the art would readily appreciate that the 
administration, duration, and dosing of the wound composi-
tions may be determined or adjusted based on the age, body 
weight, general condition, sex, diet, the severity of the wound, 
and/or degree of inflammation and/or infection associated 
with the wound. Effective amounts of the wound composition 
can be given repeatedly, depending upon the effect of the 
initial treatment regimen. Administrations are typically given 
periodically, while monitoring any response. It will be recog-
nized by a skilled person that lower or higher dosages or 
Preferred pharmaceutically acceptable derivatives include 
acids, bases, enol ethers and esters, salts, esters, hydrates, 
solvates and prodrug forms. The derivative is selected such 
that its pharmacokinetic properties are superior to the corre-
sponding neutral compound. 
30 number of applications other than those indicated herein may 
be given, according to the administration schedules and 
routes selected. In certain embodiments, the compounds may 
be provided in a composition, such as a topical composition 
or an injectable composition, in a concentration of at least 1 
Thus, effective concentrations or amounts of one or more 
of the compounds described herein or pharmaceutically 
acceptable derivatives thereof are mixed with a suitable phar-
maceutical carrier or vehicle for systemic, topical or local 
administration to form pharmaceutical compositions. The 
concentration of active compound in the composition will 
depend on absorption, inactivation, excretion rates of the 
active compound, the dosage schedule, amount administered, 
particular formulation as well as other factors known to those 
of skill in the art. 
Applications 
The compositions and methods described herein may be 
utilized to promote the healing of any type of wound. The 
wound may include any disruption in the integrity of the skin 
or tissue as a result of: an external force (e.g., trauma); a 
disease or condition; aging; a burn resulting from exposure to 
sunlight, heat, and/or chemical reaction, for example; and/or 
as a result from damage by internal physiological processes. 
The wound may be open or closed. Further, the wound may be 
characterized as a non-healing wound, which includes but is 
not limited to incomplete healing wounds, and chronic 
wounds. Incomplete healing wounds have healed to a certain 
extent, but not to the extent expected for the time duration 
involved, or have not begun healing as expected for the time 
duration involved. 
35 µM, and in particular embodiments, at least 10 µM. 
In an embodiment, the wound compositions may be admin-
istered at least once daily for at least a first week's time. 
Thereafter, the wound compositions may be applied to the 
wound at greater intervals, such as once a week, until such 
40 time as the wound is satisfactorily healed. In one embodi-
ment, a wound composition is applied once a week (after the 
initial daily application) for a period of at least seven weeks. 
It is understood that prior to each application, the wound may 
be rinsed with a sterile solution, such as saline, and allowed to 
45 dry. Thereafter, a wound composition may be applied. 
Conjunctive Agents 
In accordance with another aspect, the wound composi-
tions comprising Compounds described herein may be 
employed alone in the treatment, or may be combined with a 
50 conjunctive agent, which is administered to the patient inde-
pendently of the wound composition or as part of the same 
formulation. Such conjunctive agents may be delivered 
simultaneously, before and/or after the administration of the 
wound composition. Suitable conjunctive agents may 
55 include, by way of example only, vasodilators, vasoconstric-
tors, hypertensive agents, antibacterial agents, antibiotics, 
antioxidants, antifungal agents, non-steroidal antiinflamma-
tory agents, steroidal agents, anesthetics, and/or diabetes 
agents. 
Suitable vasodilators include, but are not limited to, mani-
dipine, nicardipine, nilvadipine, nisoldipine, nitrendipine, 
benidipine, amlodipine, aranidipine, budralazine, cadrala-
zine, ecarazine, hydralazine, todralazine, oxyphedrine, dilt-
iazem, tolazoline, hexobendine, bamethan, clonidine, meth-
In certain embodiments, the wound is a chronic wound, 60 
which may be defined as a wound that has not healed within 
three months. Exemplary chronic wounds may include arte-
rial ulcers, bum ulcers, decubitus ulcers, diabetic ulcers, dia-
betic foot ulcers, infectious ulcers, pressure ulcers, trauma-
induced ulcers, ulcerations associated with pyoderma 
gangrenosum, venous ulcers, venous stasis ulcers, and vas-
culitic ulcers. It is appreciated that the wound may be asso-
65 yldopa, guanabenz, and the like. 
Suitable vasoconstrictors include, but are not limited to, 
dopamine, dobutamine denopamine and the like. 
US 8,999,314 B2 
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Suitable hypertensive agents include, but are not limited to, 
dopamine, dobutamine, denopamine, digitoxin, digoxin, 
methyldigoxin, lanatoside C, G-strophantin, and the like. 
8 
chloride, ethyl aminobenzoate, oxethazaine, and the like, or 
other systemic, inhalation, or intravenous anesthetics. 
Suitable antibacterial agents include, but are not limited to, 
sulfonamides, such as sulfamethizole, sulfisoxazole, sulfa-
monomethoxin, sulfamethizole, salazosulfapyridine, silver 
sulfadiazine, and the like, and quinolones, such as nalidixic 
acid, pipemidic acid trihydrate, enoxacin, norfloxacin, 
ofloxacin, tosufloxacin tosilate, ciprofloxacin hydrochloride, 
lomefloxacinhydrochloride, sparfloxacin, fleroxacin, and the 
like. 
Suitable diabetes agents include, but are not limited to, 
actos, lodiglitazon, kinedak, penfill, humalin, euglucon, 
glimicron, daonil, novolin, monotard, insulins, glucobay, 
dimelin, rastinon, bacilcon, deamelin S, Iszilins]; hypothy-
roidism treating agent [dried thyroid gland (thyreoid), 
levothyroxine sodium (thyradin S), liothyronidin sodium 
(thyronine, thyromin), and the like. 
10 The ratio between a compound of the present invention and 
a conjunctive agent in a concomitant formulation may be 
selected appropriately on the basis of the target, route, and 
disease/condition of the patient and may be readily deter-
15 mined by one skilled in the art. In a particular embodiment, 
the present invention includes a method of treating a wound 
comprising administering to a patient in need thereof a wound 
composition comprising an effective amount of Compounds 
with an effective amount of an antibiotic to aid in combating 
Suitable antibiotics include, but are not limited to, tetracy-
clin hydrochloride, ampicillin, piperacillin, gentamycin, 
dibekacin, kanendomycin, lividomycin, tobramycin, amika-
cin, fradiomycin, sisomicin, tetracyclin, oxytetracyclin, roli-
tetracyclin, doxycyclin, ampicillin, piperacillin, ticarcillin, 
cefalotin, cefapirin, cefaloridine, cefaclor, cefalexin, cefroxa-
dine, cefadroxil, cefamandole, cefotoam, cefroxime, cefo-
tiam, cefotiam hexetil, cefuroxime axetil, cefdinir, cefditoren 
pivoxil, ceftazidime, cefpiramide, cefsulodin, cefinenoxime, 
cefpodoxime proxetil, cefpirome, cefozopran, cefepime, cef-
sulodin, cefinenoxime, cefinetazole, cefminox, cefoxitin, cef-
buperazone, latamoxef, flomoxef, cefazolin, cefotaxime, 
cefoperazon, ceftizoxime, moxalactam, thienamycin, sul-
fazecin, azthreonam and their salts, griseofulvin, lankacidin 25 
[J. Antibiotics, 38, 877-885 (1985)], and the like. 
20 wound infection. 
Suitable antioxidants may include, but are not limited to, 
superoxide dismutase Vitamin C (Ascorbic Acid), Vitamin D, 
Vitamin E, a-lipoic Acid, metronidazole, elemental antioxi-
dants, ~-glucan, curcumin, epigallocatechin gallate, proan- 30 
thocyanidins, propolis, honey, and the like. 
Alternative Modes of Administration 
The compounds for use in the method of the invention are 
typically formulated for topical or local administration but 
can also be formulated for oral, transdermal, sub lingual, buc-
cal, parenteral, rectal, intranasal, intraocular, intrabronchial 
or intrapulmonary administration. For oral administration the 
compounds can be of the form of tablets or capsules prepared 
by conventional means with pharmaceutically acceptable 
excipients such as binding agents (e.g., polyvinylpyrrolidone, 
hydroxypropylcellulose or hydroxypropylmethylcellulose ); 
fillers (e.g., cornstarch, lactose, microcrystalline cellulose or 
calcium phosphate); lubricants (e.g., magnesium stearate, 
talc, or silica); disintegrates (e.g., sodium starch glycollate); 
or wetting agents (e.g., sodium lauryl sulphate). If desired, the 
tablets can be coated using suitable methods and coating 
materials such as OPADRY film coating systems available 
from Colorcon, West Point, Pa. (e.g., OPADRY, OY Type, 
OY-C Type, Organic Enteric OY-P Type, Aqueous Enteric 
Suitable antifungal agents include, but are not limited to, 
polyene-based antibiotics (e.g., amphotericin B, nystatin, tri-
chomycin); griseofulvin, pyrrolnitrin, and the like; cytosine 
metabilism antagonists (e.g., flucytosine); imidazole deriva- 35 
tives (e.g., econazole, clotrimazole, miconazole nitrate, 
bifonazole, croconazole ); triazole derivatives (e.g., flucona-
zole, itraconazole, azole-based compounds, e.g., [2-[(lR, 
2R)-2-(2,4-difluorophenyl)-2-hydroxy- l-methyl-3-(1 H-1,2, 
4-t-riazol-1-yl)propyl]-4-[ 4-(2,2,3,3-tetrafluoropropoxy) 
phenyl-3-(2H,4H)-1,2,-4-triazolone ); thiocarbamic acid 
derivatives (e.g., trinaphthol); echinocandin-based deriva-
tives (e.g., caspofamgine, FK-463, V-Echinocadin), and the 
like. 
40 OY-A Type, OY-PM Type and OPADRY® White, 
32K18400). 
Suitable non-steroidal antiinflammatory agents include, 
but are not limited to, acetaminophen, fenasetin, ethenza-
mide, sulpyrine, antipyrine, migrenin, aspirin, mefenamic 
acid, flufenamic acid, diclofenac sodium, loxoprofen sodium, 
phenylbutazone, indomethacin, ibuprofen, ketoprofen, 
naproxen, oxaprozin, flurbiprofen, fenbufen, pranoprofen, 
floctafenine, epirizol, tiaramide hydrochloride, zaltoprofen, 
gabexate mesilate, camostat mesilate, ulinastatin, colchicine, 
probenecid, sulfinpyrazone, benzbromarone, allopurinol, 
sodium gold thiomalate, sodium hyaluronate, sodium salicy-
late, morphine hydrochloride, salicylic acid, atropine, scopo-
lamine, morphine, pethidine, levorphanol, ketoprofen, 
naproxen, oxymorphone, and their salts. 
In a particular embodiment, the oral form is a tablet con-
taining MCPIP and a pharmaceutically acceptable excipient, 
such as, but not limited to, mannitol, corn starch, microcrys-
45 talline cellulose, colloidal silicon dioxide, polyvinyl pyrroli-
done, talc, magnesium stearate, and the like which are option-
ally coated with an OPADRY film coating. 
Liquid preparation for oral administration can be in the 
form of solutions, syrups or suspensions. The liquid prepara-
50 tions can be prepared by conventional means with pharma-
ceutically acceptable additives such as suspending agents 
(e.g., sorbitol syrup, methyl cellulose or hydrogenated edible 
fats); emulsifying agent (e.g., lecithin or acacia); non-aque-
ous vehicles (e.g., almond oil, oily esters or ethyl alcohol); 
55 and preservatives (e.g., methyl or propyl p-hydroxy ben-
zoates or sorbic acid). 
Suitable steroidal agents include, but are not limited to, 
dexamethasone, hexestrol, methimazole, betamethasone, tri-
amcinolone, triamcinolone acetonide, fluorocinonide, fluo- 60 
rocinolone acetonide, prednisolone, methylprednisolone, 
cortisone acetate, hydrocortisone, fluorometholone, beclom-
etasone dipropionate, estriol, and the like. 
For buccal administration, the compounds for use in the 
method of the invention can be in the form of tablets or 
lozenges formulated in a conventional manner. 
For parenteral administration, the compounds for use in the 
method of the invention can be formulated for injection or 
infusion, for example, intravenous, intramuscular or subcu-
taneous injection or infusion, or for administration in a bolus 
dose and/or continuous infusion. Suspensions, solutions or 
emulsions in an oily or aqueous vehicle, optionally contain-
ing other formulatory agents such as suspending, stabilizing 
Suitable anesthetics include, but are not limited to, cocaine 
hydrochloride, procaine hydrochlodie, lidocaine, dibucaine 65 
hydrochloride, tetracaine hydrochloride, mepivacaine hydro-
chloride, bupivacaine hydrochloride, oxybuprocaine hydro- and/or dispersing agents can be used. 
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For rectal administration, the compounds for use in the 
method of the invention can be in the form of suppositories or 
enemas. 
For sublingual administration, tablets can be formulated in 
conventional manner. 
For intranasal, intraocular, intrabronchial or intrapulmo-
nary administration, conventional formulations can be 
employed. 
Further, the compounds (e.g. protein or delivery vehicle) 
for use in the method of the invention can be formulated in a 
sustained release preparation. For example, the compounds 
can be formulated with a suitable polymer or hydrophobic 
material which provides sustained and/or controlled release 
properties to the active agent compound. As such, the com-
pounds for use the method of the invention can be adminis-
tered in the form of microparticles for example, by injection 
or in the form of wafers or discs by implantation. 
Delivery Vehicles 
1) Viral Vectors 
10 
of the AAV vector, including the ITRs, the promoter and, for 
example, urease gene may be integrated into the host genome. 
The use of herpes simplex virus (HSV)-based vectors is 
discussed in detail in Cotter and Robertson, Curr. Opin. Mo!. 
Ther. 1 :633-644, 1999. HSY vectors deleted of one or more 
immediate early genes (IE) are advantageous because they 
are generally non-cytotoxic, persist in a state similar to 
latency in the host cell, and afford efficient host cell transduc-
tion. Recombinant HSY vectors can incorporate approxi-
10 mately 30 kb ofheterologous nucleic acid. A preferred HSY 
vector is one that: (1) is engineered from HSY type I, (2) has 
its IE genes deleted, and (3) contains a tissue-specific pro-
moter operably linked to a urease nucleic acid. HSY amplicon 
vectors may also be useful in various methods of the inven-
15 tion. Typically, HSY amplicon vectors are approximately 15 
kb in length, and possess a viral origin of replication and 
packaging sequences. 
Retroviruses such as C-type retroviruses and lentiviruses 
might also be used in the invention. For example, retroviral 
20 vectors may be based on murine leukemia virus (MLV). See, 
e.g., Hu and Pathak, Pharmacol. Rev. 52:493-511, 2000 and 
Fong et al., Crit. Rev. Ther. Drug Carrier Syst. 17: 1-60, 2000. 
MLV-based vectors may contain up to 8 kb ofheterologous 
In accordance with the method of the invention, an expres-
sion vector is a viral or a non-viral expression vector. Viral 
expression vectors which may be used advantageously in the 
method of the invention include, but are not limited to, an 
adeno associated virus (AAV) vector, a lentivirus vector, an 
adenovirus vector, and a herpes simplex virus (HSY) vector. 25 
(therapeutic) DNA in place of the viral genes. 
Additional retroviral vectors that might be used are repli-
In a preferred embodiment, the compositions of the inven-
tion can be tailored to include a nucleic acid sequence (e.g., 
SEQ ID NO: 1, derivatives, fragments and variants thereof) in 
an expression vector. Viral vectors for use in the invention are 
those that exhibit low toxicity to a host cell. Viral vector 
methods and protocols that may be used in the invention are 
reviewed in Kay et al. Nature Medicine 7:33-40, 2001. The 
use of specific vectors, including those based on adenovi-
ruses, adeno-associated viruses, herpes viruses, and retrovi-
ruses are described in more detail below. 
The use of recombinant adenoviruses as vectors is dis-
cussed in W. C. Russell, Journal of General Virology 
81:2573-2604, 2000; and Bramson et al., Curr. Opin. Bio-
technol. 6:590-595, 1995. Adenovirus vectors are preferred 
for use in the invention because they (1) are capable of highly 
efficient gene expression in target cells and (2) can accom-
modate a relatively large amount ofheterologous (non-viral) 
DNA. A preferred form of recombinant adenovirus is a "gut-
less", "high-capacity", or "helper-dependent" adenovirus 
vector. Such a vector features, for example, (1) the deletion of 
all or most viral-coding sequences (those sequences encoding 
viral proteins), (2) the viral inverted terminal repeats (ITRs) 
which are sequences required for viral DNA replication, (3) 
up to 28-32 kb of"exogenous" or "heterologous" sequences 
(e.g., sequences encoding an ammonia producing enzyme), 
and ( 4) the viral DNA packaging sequence which is required 
for packaging of the viral genomes into infectious capsids. 
For specifically targeting liver, preferred variants of such 
recombinant adenoviral vectors contain tissue-specific 
enhancers and promoters operably linked to for example, 
SEQIDNO: 1. 
cation-defective lentivirus-based vectors, including human 
immunodeficiency (HIV)-based vectors. See, e.g., Vigna and 
Naldini, J. Gene Med. 5:308-316, 2000 and Miyoshi et al., J. 
Viral. 72:8150-8157, 1998. Lentiviral vectors are advanta-
30 geous in that they are capable ofinfecting both actively divid-
ing and non-dividing cells. They are also highly efficient at 
transducing human epithelial cells. Lentiviral vectors for use 
in the invention may be derived from human and non-human 
(including SIV) lentiviruses. Preferred lentiviral vectors 
35 include nucleic acid sequences required for vector propaga-
tion as well as a tissue-specific promoter operably linked to, 
for example, SEQ ID NO: 1, derivatives, variants and frag-
ments thereof. These former may include the viral LTRs, a 
primer binding site, a polypurine tract, att sites, and an 
40 encapsidation site. 
A lentiviral vector may be packaged into any suitable len-
tiviral capsid. The substitution of one particle protein with 
another from a different virus is referred to as "pseudotyp-
ing". The vector capsid may contain viral envelope proteins 
45 from other viruses, including murine leukemia virus (MLV) 
or vesicular stomatitis virus (VSV). The use of the VSV 
G-protein yields a high vector titer and results in greater 
stability of the vector virus particles. 
Alphavirus-based vectors, such as those made from sem-
50 liki forest virus (SFV) and sindbis virus (SIN), might also be 
used in the invention. Use of alphaviruses is described in 
Lundstrom, K., Intervirology 43:247-257, 2000 and Perri et 
al., Journal ofVirology 74:9802-9807, 2000. Alphavirus vec-
tors typically are constructed in a format known as a rep Ii con. 
55 A rep Ii con may contain (1) alphavirus genetic elements 
required for RNA replication, and (2) a heterologous nucleic 
acid such as one encoding SEQ ID NO: 1. Within an alphavi-
rus replicon, the heterologous nucleic acid may be operably 
Other viral vectors that might be used in the invention are 
adeno-associated virus (AAV)-based vectors. AAV-based 
vectors are advantageous because they exhibit high transduc-
tion efficiency of target cells and can integrate into the host 60 
genome in a site-specific manner. Use of recombinant AAV 
vectors is discussed in detail in Tai, J., J. Biomed. Sci. 7:279-
291, 2000 and Monahan and Samulski, Gene Therapy 7:24-
30, 2000. A preferred AAV vector comprises a pair of AAV 
inverted terminal repeats which flank at least one cassette 
containing a tissue (e.g., gum)- or cell-specific promoter 
operably linked to a urease nucleic acid. The DNA sequence 
linked to a tissue-specific promoter or enhancer. 
Recombinant, replication-defective alphavirus vectors are 
advantageous because they are capable of high-level heter-
ologous (therapeutic) gene expression, and can infect a wide 
host cell range. Alphavirus replicons may be targeted to spe-
cific cell types by displaying on their virion surface a func-
65 tional heterologous ligand or binding domain that would 
allow selective binding to target cells expressing a cognate 
binding partner. Alphavirus replicons may establish latency, 
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and therefore long-term heterologous nucleic acid expression 
in a host cell. The replicons may also exhibit transient heter-
ologous nucleic acid expression in the host cell. A preferred 
alphavirus vector or replicon is non-cytopathic. 
12 
Polynucleotides and Polypeptides 
Aspects of the invention therefore include polynucleotides 
encoding at least one mammalian MCPIP and amino acid 
sequences representing at least one MCPIP protein. Aspects 
of the invention also include subunits or variants of poly-
nucleotides or MCPIP proteins or peptides encoded by those 
polynucleotides. The terms "protein" and "polypeptide" are 
used interchangeably herein, unless specified otherwise. 
It is well known in the art that a single amino acid may be 
In many of the viral vectors compatible with methods of the 
invention, more than one promoter can be included in the 
vector to allow more than one heterologous gene to be 
expressed by the vector. Further, the vector can comprise a 
sequence which encodes a signal peptide or other moiety 
which facilitates the secretion of a gene product from the host 
cell. 
To combine advantageous properties of two viral vector 
systems, hybrid viral vectors may be used to deliver a nucleic 
acid to a target tissue. Standard techniques for the construc-
tion of hybrid vectors are well-known to those skilled in the 
art. Such techniques can be found, for example, in Sambrook, 
et al., In Molecular Cloning: A laboratory manual. Cold 
Spring Harbor, N.Y. or any numberoflaboratory manuals that 
discuss recombinant DNA technology. Double-stranded 
AAV genomes in adenoviral capsids containing a combina-
tion of AAV and adenoviral lilts may be used to transduce 
cells. In another variation, anAAV vector may be placed into 
10 encoded by more than one nucleotide codon-and that the 
nucleotide sequence may be easily modified to produce an 
alternate nucleotide sequence that encodes the same peptide. 
Therefore, alternate embodiments of the present invention 
include alternate DNA sequences encoding peptides contain-
15 ing the amino acid sequences described for MCPIP. DNA 
sequences encoding peptides containing the claimed amino 
acid sequence include DNA sequences which encode any 
combination of the claimed sequence and any other amino 
acids located N-terminal or C-terminal to the claimed amino 
20 acid sequence. 
a "gutless", "helper-dependent" or "high-capacity" adenovi-
ral vector. Adenovirus/AAV hybrid vectors are discussed in 
Lieber et al., J. Viral. 73:9314-9324, 1999. Retrovirus/aden- 25 
ovirus hybrid vectors are discussed in Zheng et al., Nature 
Biotechnol. 18: 176-186, 2000. Retroviral genomes contained 
within an adenovirus may integrate within the host cell 
genome and effect stable urease gene expression. 
Other nucleotide sequence elements which facilitate 30 
expression of SEQ ID NO: 1, derivatives, variants and frag-
ments thereof and cloning of the vector are further contem-
plated. For example, the presence of enhancers upstream of 
the promoter or terminators downstream of the coding region, 
It is to be understood that amino acid and nucleic acid 
sequences may include additional residues, particularly N- or 
C-terminal amino acids or 5' or 3' nucleotide sequences, and 
still be essentially as set forth in the sequences disclosed 
herein, as long as the sequence produces a functionally simi-
lar polypeptide or protein. A nucleic acid fragment of almost 
any length may be employed, and may be combined with 
other DNA sequences, such as promoters, polyadenylation 
signals, additional restriction enzyme sites, multiple cloning 
sites, other coding segments, and the like. Therefore, overall 
length may vary considerably. 
MCPIP polypeptides, as used herein, may comprise short 
fragments of proteins often referred to as peptides, as well as 
longer fragments generally referred to as polypeptides, and 
for example, can facilitate expression. 35 full-length proteins. These polypeptides can be prepared by 
standard peptide synthesis methods known to those of skill in 
the art, but may also be produced using an expression vector 
having a polynucleotide sequence encoding the polypeptide 
In an aspect of the method wherein the viral expression 
vector is anAAV vector capable of transducing the target cell, 
the AAV vector is free of both wildtype and helper virus. 
Exemplary types of AAV vectors useful in the present inven-
tion include serotype 2 AA V vectors and chimeric serotype 1h 40 
AAV vectors. 
2) Other Delivery Vehicles 
Many nonviral techniques for the delivery of a nucleic acid 
sequence into a cell can be used, including direct naked DNA 
uptake (e.g., Wolff et al., Science 247: 1465-1468, 1990), 45 
receptor-mediated DNA uptake, e.g., using DNA coupled to 
asialoorosomucoid which is taken up by the asialoglycopro-
tein receptor in the liver (Wu and Wu, J. Biol. Chem. 262: 
4429-4432, 1987; Wu et al., J. Biol. Chem. 266: 14338-
14342, 1991), and liposome-mediated delivery (e.g., Kaneda 50 
eta!., Expt. Cell Res. 173: 56-69, 1987; Kanedaetal., Science 
243: 375-378, 1989; Zhu et al., Science 261: 209-211, 1993). 
Many of these physical methods can be combined with one 
another and with viral techniques; enhancement ofreceptor-
mediated DNA uptake can be effected, for example, by com- 55 
bining its use with adenovirus (Curiel et al., Proc. Natl. Acad. 
Sci. USA 88: 8850-8854, 1991; Cristiano et al., Proc. Natl. 
Acad. Sci. USA 90: 2122-2126, 1993). Other examples 
include stem cells such as mesenchymal stem cells, hemato-
poietic stem cells, cardiac stem cells or neural stem cells, 60 
embryonic stem cells that have been engineered to express 
MCPIP. Such stem cells can be administered in such a way to 
be incorporated in to tissues of a patient in need. In a particu-
lar embodiment, stem cells are administered to myocardial 
tissue. Bu L, et al "Human ISL! heart progenitors generate 65 
diverse multipotent cardiovascular cell lineages" Nature 
2009 460:113-117. 
(s) of choice operably linked to appropriate promoter, termi-
nator, and other functional sequences (such as a sequence 
encoding a purification tag) to facilitate expression and puri-
fication of the peptides. 
It is to be understood that amino acid and nucleic acid 
sequences may include additional residues, particularly N- or 
C-terminal amino acids or 5' or 3' nucleotide sequences, and 
still be essentially as set forth in the sequences disclosed 
herein, as long as the sequence confers MCP-1 inducible 
transcription factor activity upon the polypeptide or protein 
moiety of the expressed protein. Nucleic acids which hybrid-
ize with a nucleic acid encoding the amino acid sequence of 
SEQ ID NO: 2 or SEQ ID NO: 4 under stringent conditions 
and encode a polypeptide having a similar MCP-1 inducible 
transcription factor activity to that of a polypeptide compris-
ing SEQ ID NO: 2 or SEQ ID NO: 4 are also included as 
embodiments of the present invention. 
The term "moderately stringent conditions", as used 
herein, means conditions in which non-specific hybridization 
will not generally occur. Hybridization under such conditions 
can be performed based on the description provided in 
Molecular Cloning: A Laboratory Manual 2nd ed., published 
by cold Spring Harbor Laboratory in 1989, edited by T. 
Maniatis et al. Typically, for stringent hybridization condi-
tions a combination of temperature and salt concentration 
should be chosen that is approximately 12-20° C. below the 
calculated Tm of the hybrid under study. The Tm of a hybrid 
between a polynucleotide of interest or the complement 
thereof and a polynucleotide sequence which is at least about 
US 8,999,314 B2 
13 
50, preferably about 75, 90, 96, or 98% identical to one of 
those nucleotide sequences can be calculated, for example, 
using the equation of Bolton and McCarthy, Proc. Natl. Acad. 
Sci. U.S.A. 48, 1390 (1962): 
Tm ~81.5° C.-16.6(log 10 [Na•])+0.41(%G+C)-0.63 
(%formamide)-600/l), 
where I=the length of the hybrid in basepairs. 
Stringent wash conditions include, for example, 4xSSC at 
65° C., or 50% formamide, 4xSSC at 42° C., or 0.5xSSC, 
0.1 % SDS at 65° C. Highly stringent wash conditions include, 
for example, 0.2xSSC at 65° C. According to another 
example, stringent conditions include incubation with a probe 
in 6xSSC containing 0.5% SDS, 5xDenhardt's solution and 
100 micrograms/ml salmon sperm DNA at 60 degrees C. 
Additional nucleic acid bases may be added either 5' or 3' 
to the MCPIP ORF, and may be combined with other DNA 
sequences, such as promoters, polyadenylation signals, addi-
tional restriction enzyme sites, multiple cloning sites, other 
coding segments, and the like. Therefore, overall length of 
such a polynucleotide may vary considerably. In a method 
described by the present invention, a nucleotide sequence of 
SEQ ID NO: 1 is inserted into a protein expression vector to 
produce a protein which can be used to synthesize a DNA 
copy of an RNA molecule. The DNA can then be amplified to 
form multiple copies. 
"Control sequences" are those DNA sequences that are 
necessary for the expression of a protein from a polynucle-
otide sequence containing such a sequence, operably linked 
to the polynucleotide sequence encoding the protein. These 
sequences include prokaryotic sequences such as, for 
example, promoters, operators, and ribosome binding sites, 
and eukaryotic sequences such as, for example, promoters, 
enhancers, and polyadenylation signals. "Expression sys-
tems" are DNA sequences (such as, for example, plasmids) 
appropriate for expression of a target protein in a particular 
host cell, these sequences comprising appropriate control 
sequences for protein expression in the host cell operably 
linked to the polynucleotide sequence encoding the target 
protein. 
It is to be understood that a "variant" of a polypeptide is not 
completely identical to the native protein. A variant MCPIP 
protein, for example, can be obtained by altering the amino 
acid sequence by insertion, deletion or substitution of one or 
more amino acids. The amino acid sequence of the protein can 
be modified, for example, by substitution to create a polypep-
tide having substantially the same or improved qualities as 
compared to the native polypeptide. The substitution may be 
a conserved substitution. A "conserved substitution" is a sub-
stitution of an amino acid with another amino acid having a 
side chain that is similar in polar/nonpolar nature, charge, or 
size. The 20 essential amino acids can be grouped as those 
having nonpolar side chains (alanine, valine, leucine, isoleu-
cine, praline, phenylalanine, and tryptophan), uncharged 
polar side chains (methionine, glycine, serine, threonine, cys-
tine, tyrosine, asparagine and glutamine ), acidic side chains 
( aspartate and glutamate), and basic side chains (lysine, argi-
nine, and histidine). Conserved substitutions might include, 
for example, Asp to Glu, Asn, or Gin; His to Lys, Arg or Phe; 
Asn to Gin, Asp or Glu; and Ser to Cys, Thr or Gly. Alanine, 
for example, is often used to make conserved substitutions. 
To those of skill in the art, variant polypeptides can be 
obtained by substituting a first amino acid for a second amino 
acid at one or more positions in the polypeptide structure in 
order to affect biological activity. Amino acid substitutions 
may, for example, induce conformational changes m a 
polypeptide that result in increased biological activity. 
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Those of skill in the art may also make substitutions in the 
amino acid sequence based on the hydrophilicity index or 
hydropathic index of the amino acids. A variant amino acid 
molecule of the present invention, therefore, has less than one 
hundred percent, but at least about fifty percent, and prefer-
ably at least about eighty to about ninety percent amino acid 
sequence homology or identity to the amino acid sequence of 
a polypeptide comprising SEQ ID NO: 2, or a polypeptide 
encoded by SEQ ID NO: 4. Therefore, the amino acid 
10 sequence of the variant MCPIP protein corresponds essen-
tially to the native MCPIP protein amino acid sequence. As 
used herein, "corresponds essentially to" refers to a polypep-
tide sequence that will elicit a similar biological and enzy-
matic activity to that generated by a MCPIP protein compris-
15 ing SEQ ID NO 2 or SEQ ID NO: 4, such activity being at 
least about 70 percent that of the native MCPIP protein, and 
more preferably greater than 90 percent of the activity of the 
native MCPIP protein. 
A variant of the MCPIP protein may include amino acid 
20 residues not present in a corresponding MCPIP protein com-
prising SEQ ID NO 2, or may include deletions relative to the 
MCPIP protein comprising SEQ ID NO 2. A variant may also 
be a truncated "fragment," as compared to the corresponding 
protein comprising SEQ ID NO 2, the fragment being only a 
25 portion of the full-length protein. 
Polypeptides of the invention may be delivered to a cell via 
attachment of one or more polypeptides to cell permeable, or 
"importation competent" signal peptide sequences, and 
membrane translocation sequences that have been shown to 
30 facilitate the transport of attached peptides and proteins into 
cells. Several sequences of this kind have previously been 
described, including the hydrophobic region of the signal 
sequence of Kaposi fibroblast growth factor which has been 
fused to the nuclear localization sequence (NLS) of p50 to 
35 producethepeptideknownas SN50 (U.S. Pat. No. 5,807,746, 
Lin et al.). Polypeptides may also be delivered via a mem-
brane translocating sequence described in U.S. Pat. Nos. 
6,248,558; 6,432,680; and 6,780,843 (Rojas et al.). MCPIP, 
or a nuclear localization sequence that blocks nuclear local-
40 ization ofMCPIP, may also be delivered via the cell-perme-
able sequence described in U.S. Patent Application Number 
20060099275 (Lin and Budu). Other membrane-translocat-
ing sequences are also well-known to those of skill in the art. 
Non-invasive delivery of proteins via membrane translocat-
45 ing peptides is discussed by Hawiger in Curr. Opin Chem. 
(1999) 3: 89-94, and multiple examples of both in vitro and in 
vivo use of membrane translocation via cell-permeable pep-
tide sequences are available in the literature. The HIV-Tat 
peptide, for example, has been used in a number of studies to 
50 deliver cargo peptides to target cells (Ribeiro, M. M., et al. 
Biochem. Biophys. Res. Commun. (2003) 305(4): 876-81; 
Jung, H.J., et al. Biochem. Biophys. Res. Commun. (2006) 
345(1): 222-228; Barnett, E. M., et al. Invest. Ophthalmol. 
Vis. Sci. (2006) 47(6): 2589-2595; Hoque, M., et al. J. Biol. 
55 Chem. (2005) 280(14): 13648-13657; Monda! D., et al. Exp. 
Biol. Med. (2005) 230(9): 631-644; Kittiworakam, J., et al. J. 
Biol. Chem. (2006) 281(6): 3105-3115). 
Polynucleotides encoding all or a part of the amino acid 
sequence ofMCPIP may be delivered in vitro or in vivo by a 
60 variety of means known to those of skill in the art, such as, for 
example, viral gene delivery, naked DNA, delivery via cat-
ionic lipid carriers, and plasmid DNA/poly lysine complexes. 
As used herein, MCPIP polypeptides include variants or 
biologically active fragments of the peptides, as well as pep-
65 tides which may contain additional amino acids either N-ter-
minal or C-terminal (or both) to the disclosed sequences, their 
derivatives, variants, or functional counterparts. A "func-
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tional counterpart" can include, for example, a peptide 
nucleic acid (PNA). A "variant" of the peptide is not com-
pletely identical to a disclosed MCPIP polypeptide sequence. 
A variant, given the disclosure of the present invention, can be 
obtained by altering the amino acid sequence by insertion, 5 
deletion or substitution of one or more amino acid. The amino 
acid sequence of a disclosed peptide can be modified, for 
example, by substitution to create a peptide having substan-
tially the same or improved qualities. The substitution may be 
a conserved substitution. A "conserved substitution" is a sub- 10 
stitution of an amino acid with another amino acid having a 
side chain that is similar in polar/nonpolar nature, charge, or 
size. The 20 essential amino acids can be grouped as those 
having nonpolar side chains (alanine, valine, leucine, isoleu-
cine, praline, phenylalanine, and tryptophan), uncharged 15 
polar side chains (methionine; glycine, serine, threonine, cys-
teine, tyrosine, asparagine and glutamine ), acidic side chains 
( aspartate and glutamate) and basic side chains (lysine, argi-
nine, and histidine). Conserved substitutions might include, 
for example, Asp to Glu, Asn or Gin; His to Lys, Arg or Phe; 20 
Asn to Gin, Asp or Glu, Leu to Ile or Val, and Ser to Cys, Thr 
or Gly. Alanine is commonly used to make conserved substi-
tutions. 
To those of skill in the art, variant polypeptides can be 
obtained by substituting a first amino acid for a second amino 25 
acid at one or more positions in the peptide structure in order 
to affect biological activity. Amino acid substitutions may, for 
example, induce conformational changes in a polypeptide 
that result in increased biological activity. Those of skill in the 
art may also make substitutions in the amino acid sequence 30 
based on the hydrophilicity index or hydropathic index of the 
amino acids. 
A variant polypeptide of the present invention has less than 
100%, but at least about 50%, and more preferably at least 
about 80% to about 90% amino acid sequence homology or 35 
identity to the amino acid sequence of a corresponding native 
nucleic acid molecule or polypeptide comprising SEQ ID NO 
1, SEQ ID NO 2, SEQ ID NO 3, or SEQ ID NO 4. The amino 
acid sequence of a variant MCPIP polypeptide therefore cor-
responds essentially to the disclosed amino acid sequences. 40 
As used herein, "corresponds essentially to" refers to a 
polypeptide sequence that will elicit a similar biological 
activity as that generated by a disclosed MCPIP, such activity 
being from at least about 70 percent of that of disclosed 
MCPIP polypeptide, to greater than 100 percent of the activ- 45 
ity of a disclosed MCPIP peptide. 
The human MCPIP polypeptide sequence comprises a 
Zc3h12a Ribonuclease domain at residues 130-280 and zinc 
finger domain at 284-309. It is to be understood that non-
conserved substitutions at these regions will likely result in 50 
negating activity of the protein. Mizgalska et al., FEBS Jour-
nal 276:7386-7399 (2009). Conserved substitutions in these 
domains will likely result in preserving activity of the protein. 
Most mutations, whether conservative or non-conservative, 
outside the two domains will not likely affect activity of the 55 
protein to any great extent. Accordingly, the disclosure of 
SEQ ID NO: 2 combined with the knowledge in the art 
regarding the genetic code establishes possession of using the 
genus of nucleic acid sequences that encode SEQ ID NO. 2, as 
well as sequences that encode a polypeptide with at least 85 60 
percent sequence identity with SEQ ID NO. 2. 
A variant of a disclosed MCPIP may include amino acid 
residues not present in the corresponding MCPIP, or may 
include deletions relative to the corresponding MCPIP. A 
variant may also be a truncated "fragment" as compared to the 65 
corresponding MCPIP, i.e., only a portion of the amino acid 
sequence of certain disclosed MCPIPs. The fragment may be 
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atleast20, 30, 40, 50, 60, 80, 90, 100, 150, 175, 200, 250, 300, 
350, 400, 450, 500, 550, 560, 570, 580, 585, 590, or 595 
amino acids in length. 
Variants, including fragments, possessing activity of 
MCPIP, refer to those, that are capable of degrading interleu-
kin I-beta (see Mizgalska et al.). Alternatively, the variant has 
activity according to the in vitro assay for transcription factor 
activity as taught in Zhou et al., Circulation Research, 
98: 1177-1185 (2006). Preferably, naturally or non-naturally 
occurring polypeptide variants have amino acid sequences 
which are at least about 55, 60, 65, or 70, preferably about 75, 
80, 85, 90, 96, 96, or 98% identical to the full-length amino 
acid sequence or a fragment thereof. Percent identity between 
a putative polypeptide variant and a full length amino acid 
sequence is determined using the Blast2 alignment program 
(Blosum62, Expect 10, standard genetic codes). 
EXAMPLES 
Example 1 
Expression ofMCPIP on Scratch-Induced Wound 
Healing in HaCaT Cells 
Cells were cultured to confluence and transfected with 
GFP or MCPIP vectors for 48 hrs and wounded by scratching. 
Cells were then incubated for the indicated hours and photo-
graphed. See FIG. lA. The scratch induced wound healing 
during 24 hrs after scratching was then quantified. The wound 
distance was quantified and it was shown enhanced expres-
sion of MCPIP caused a significant decrease in wound dis-
tance. This was correlated with HaCAt cell migration. see 
FIG. lB. 
Example 2 
Knockdown of MCPIP Inhibited Migration of 
HaCaT Cells 
HaCaT cells were cultured and transfected with MCPIP 
siRNA or non-targeted siRNA for 48 hrs. RT-PCR was per-
formed to confirm that siRNA efficiently knockdown of 
MCPIP mRNA levels. FIG. 2A is a photograph of a gel of 
RT-PCR samples showing that MCPIP siRNA efficiently 
knocks down MCPIP. HaCaT Cells were cultured to conflu-
ence and wounded by scratching. Cells were then incubated 
for 0, 12, and 24 hours and then photographed (FIG. 2b). 
Migration of the cells proximate to the scratch wound was 
measured at 24 hours. FIG. 2C shows that HaCaT cells trans-
fected with MCPIP siRNA show a significant decrease in 
migration. 
Example 3 
Lack ofMCPIP Impaired Wound Healing in MCPIP 
KO Mice 
(A) Wounds were formed on the epidermis ofMCPIP KO 
mice and wild type mic. Wound sites were photographed at 
day 7 and day 12. FIG. 3A clearly shows that the level of 
wound healing in the MCPIP knockout mice is significantly 
less in as compared to wild-type. Changes in percentage of 
wound area at the day 7 and day 12 time points of the knock-
out and wild-type mice were compared with the original 
wound area. The percentage of the wound area at day 7 and 12 
is dramatically greater in the knockout mice as compared to 
wild-type (FIG. 3C). 
US 8,999,314 B2 
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Example 4 
Expression of MCPIP Enhanced Wound Healing in 
Diabetic Mice 
Induction ofMCPIP was found in the wound skin but not in 
the healed skin (see FIG. 4). As shown in FIG. 4(B), wound 
sites were photographed at day 0, 3, 7 and 12. Day O pictures 
were taken immediately after the wound. Changes in percent-
age of wound area at each time point compared with the 10 
original wound area, which is shown in FIG. 4C. The level of 
healing in the MCPIP enhanced animals is clearly greater 
than the control. FIG. 4D shows the expression of cytokines in 
wound skins at day 12 after wound. Expression of PECAM 
and VEFF in wound skins at day 12 was examined by RT-PCR 15 
(see FIG. 4F). 
Unless otherwise defined, all technical and scientific terms 
used herein have the same meaning as commonly understood 
by one of ordinary skill in the art of molecular biology. 
Although methods and materials similar or equivalent to 20 
those described herein can be used in the practice or testing of 
the present invention, suitable methods and materials are 
described herein. All publications, patent applications, pat-
ents, and other references mentioned herein are incorporated 
by reference in their entirety. In case of conflict, the present 25 
specification, including definitions, will control. In addition, 
the materials, methods, and examples are illustrative only and 
are not intended to be limiting. 
18 
Numerous variations, changes and substitutions may be made 
without departing from the invention herein. Accordingly, it 
is intended that the invention be limited only by the spirit and 
scope of the appended claims. The teachings of all patents and 
other references cited herein are incorporated herein by ref-
erence in their entirety to the extent they are not inconsistent 
with the teachings herein. 
What is claimed is: 
1. A topical composition for application to a wound in a 
subject to promote healing of the wound, the wound compo-
sition comprising: 
an effective amount ofMCPIP polypeptide for treatment of 
the wound; and 
a pharmaceutically acceptable carrier in a form configured 
for topical administration to the subject. 
2. The topical composition of claim 1, which is in a form 
selected from the group consisting of a solution, a suspension, 
a spray, a cream, a gel, a foam, an ointment, a lotion, and a 
powder. 
3. The topical composition of claim 1, wherein the phar-
maceutically acceptable carrier comprises a dressing, the 
dressing selected from the group consisting of a transdermal 
patch, a pad, a powder, a matrix, and a bandage. 
4. A kit comprising: 
a pharmaceutical composition comprising an effective 
amount of MCPIP for treating a wound and a pharma-
ceutically acceptable carrier; and 
instructions directing a user to use of the pharmaceutical 
composition in the treatment of a wound in a subject. 
5. The kit of claim 4, wherein the wound is at least one of 
a wound selected from the group consisting of an incomplete 
healing wound, a chronic wound, a bum, and a wound caused 
by trauma. 
. ~· T~e. kit of claim 4, wherein the pharmaceutical compo-
s1t10n 1s m a form from the group consisting of a solution, a 
suspension, a spray, a cream, a gel, a foam, an ointment, a 
lotion, or a powder. 
Reference is made to standard textbooks of molecular biol-
ogy that contain definitions and methods and means for car- 30 
rying out basic techniques, encompassed by the present 
invention. See, for example, Maniatis et al., Molecular Clon-
ing: A Laboratory Manual, Cold Spring Harbor Laboratory 
Press, New York (1982) and Sambrook et al., Molecular Clon-
ing: A Laboratory Manual, Cold Spring Harbor Laboratory 35 
Press, New York (1989); Methods in Plant Molecular Biol-
ogy, Maliga et al, Eds., Cold Spring Harbor Laboratory Press, 
New York (1995); Arabidopsis, Meyerowitz et al, Eds., Cold 
Spring Harbor Laboratory Press, New York (1994) and the 
various references cited therein. 
7. The kit of claim 4, wherein the pharmaceutically accept-
40 able carrier comprises a dressing, the dressing selected from 
the group consisting of a transdermal patch, a pad, a powder, 
a matrix, and a bandage. 
Finally, while various embodiments of the present inven-
tion have been shown and described herein, it will be obvious 
that such embodiments are provided by way of example only. * * * * * 
